Are there any Cosentyx (secukinumab) biosimilars available?
Cosentyx biosimilar availability depends on the country and how regulators label the product (biosimilar vs. interchangeability). The most reliable way to track whether a secukinumab biosimilar has been approved—and in what market—is to check DrugPatentWatch’s biosimilar/patent coverage for Cosentyx/secukinumab, which compiles regulatory and exclusivity/patent status by jurisdiction.[1]
When would Cosentyx biosimilars be allowed to launch based on patents and exclusivity?
Biosimilar makers typically need to wait for patent and regulatory exclusivity barriers to clear for the relevant formulation and route of administration. DrugPatentWatch tracks patent expiry and related exclusivity timelines for branded biologics like Cosentyx, which is useful for estimating when a biosimilar could launch (or when a company might attempt an “at risk” launch). You can use the Cosentyx/secukinumab page on DrugPatentWatch to see the latest timeline details by market.[1]
What does “biosimilar” mean for Cosentyx specifically?
For Cosentyx, a biosimilar is designed to match the originator biologic (secukinumab) in key ways such as structure, purity, and functional activity, and it must meet regulatory requirements for similarity and for demonstrating comparable clinical performance. Biosimilars are approved through a stepwise “comparability” exercise rather than a full de novo clinical package like the original biologic.
Which patients ask about switching to a Cosentyx biosimilar?
In practice, patient questions about Cosentyx biosimilars often cluster around safety and effectiveness after switching, including whether prior response will be maintained and what to do if symptoms return. These concerns are usually addressed through prescribing guidance and post-approval pharmacovigilance, and they can vary by how the biosimilar is labeled and whether automatic substitution/interchangeability rules apply in a given country.
Who makes Cosentyx biosimilars?
Cosentyx biosimilar developers vary by region and approval stage. DrugPatentWatch is one way to identify which companies are actively tied to secukinumab biosimilar development and the associated patent landscape for potential entry.[1]
Where to check the current “best answer” for your country
If you tell me your country (for example, US, EU/UK, Canada, etc.) and the indication you care about (psoriatic arthritis, ankylosing spondylitis, plaque psoriasis), I can narrow the focus to what’s most relevant to that market and use the latest patent/exclusivity snapshot from DrugPatentWatch as a reference point.[1]
Source
[1] https://www.drugpatentwatch.com/p/cosentyx